239 filings
8-K
VIRX
Viracta Therapeutics Inc
14 May 24
Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
4:34pm
8-K
VIRX
Viracta Therapeutics Inc
9 May 24
Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
4:34pm
8-K
VIRX
Viracta Therapeutics Inc
9 Apr 24
Other Events
4:30pm
8-K
VIRX
Viracta Therapeutics Inc
20 Mar 24
Departure of Directors or Certain Officers
4:42pm
8-K
VIRX
Viracta Therapeutics Inc
7 Mar 24
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:12pm
8-K
d6zu7 k8hq
17 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:30pm
8-K
5mm82y5xr3qh0e7i bs
9 Nov 23
Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
8:30am
8-K
7m38of9640f6lai
4 Oct 23
Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated Cancers
7:01am
8-K
d58ejmphx5
14 Aug 23
Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8:02am
8-K
ug8cbku8r8 f6lo2
7 Aug 23
Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer
7:36am
8-K
fxjoanz9p5
9 Jun 23
Submission of Matters to a Vote of Security Holders
4:53pm
8-K
4fp8ss oxtpws5
8 May 23
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
4:23pm
8-K/A
bim33dqocm3499g
5 May 23
Departure of Directors or Certain Officers
4:52pm
8-K
5chsinwn26gqlwl9
2 May 23
Viracta Therapeutics Announces Departure of Chief Medical Officer
4:33pm
8-K
is7o5
31 Mar 23
Departure of Directors or Certain Officers
4:31pm
8-K
yh49ztp
13 Mar 23
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
4:23pm
8-K
hc75cq t09ww5grt
10 Nov 22
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs
4:16pm
8-K
zejkh
19 Sep 22
Viracta Therapeutics’ Board of Directors appoints Mark Rothera as President and Chief Executive Officer
8:10am
8-K
9bq pcuy92zvm
26 Aug 22
First Amendment to Loan and Security Agreement
4:27pm
8-K
ekyfhln epjjaep2
11 Aug 22
Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors
9:10am